AIM: To study whether adalimumab (ADA) was associated with improvement in growth, bone mineral density (BMD) and bone metabolism. METHODS: In children with Crohn's disease (CD) there is a high prevalence of growth failure and reduced BMD. Treatment with infliximab is associated with an improvement in growth. Anthropometry, paediatric CD activity index (PCDAI), bone markers and BMD was measured in 18 patients (72% females) one year before and after start of ADA with a median age of 14.4 years (range: 5-19 years) at treatment start. Outcomes were indicators of growth with treatment as well as interval growth. RESULTS: Eleven (61%) children experienced catch-up growth after ADA. PCDAI significantly decreased from 52.1 ± 16 to 30.4 ± 23 (P ≤ 0.001). Post ADA, body mass index (BMI) standard deviation score (SDS) 0.1[range: 2.7-(-0.8)] vs -1 [range: 0.1-(-3.6)], P = 0.04 and ∆BMI SDS in children 0.3 [range: 0.7-(-0.2)] vs -1.1 [range: 1.2-(-2.3)], P = 0.01 in remission were significantly higher compared to those with moderate to severe inflammation. The main predictors for growth were 25-hydroxycholecalciferol and for bone mineralisation weight and height SDS. ADA had no significant influence on bone markers and BMD. CONCLUSION: Next to improvement of PCDAI, half of the children achieved a positive catch-up growth. A better nutritional status with improvement in BMI and weight is positive predictor for improved growth and bone mineralisation.
AIM: To study whether adalimumab (ADA) was associated with improvement in growth, bone mineral density (BMD) and bone metabolism. METHODS: In children with Crohn's disease (CD) there is a high prevalence of growth failure and reduced BMD. Treatment with infliximab is associated with an improvement in growth. Anthropometry, paediatric CD activity index (PCDAI), bone markers and BMD was measured in 18 patients (72% females) one year before and after start of ADA with a median age of 14.4 years (range: 5-19 years) at treatment start. Outcomes were indicators of growth with treatment as well as interval growth. RESULTS: Eleven (61%) children experienced catch-up growth after ADA. PCDAI significantly decreased from 52.1 ± 16 to 30.4 ± 23 (P ≤ 0.001). Post ADA, body mass index (BMI) standard deviation score (SDS) 0.1[range: 2.7-(-0.8)] vs -1 [range: 0.1-(-3.6)], P = 0.04 and ∆BMI SDS in children 0.3 [range: 0.7-(-0.2)] vs -1.1 [range: 1.2-(-2.3)], P = 0.01 in remission were significantly higher compared to those with moderate to severe inflammation. The main predictors for growth were 25-hydroxycholecalciferol and for bone mineralisation weight and height SDS. ADA had no significant influence on bone markers and BMD. CONCLUSION: Next to improvement of PCDAI, half of the children achieved a positive catch-up growth. A better nutritional status with improvement in BMI and weight is positive predictor for improved growth and bone mineralisation.
Entities:
Keywords:
Adalimumab; Bone health; Crohn’s disease; Growth; Paediatrics
Authors: Maria T Abreu; Jordan L Geller; Eric A Vasiliauskas; Lori Y Kam; Puja Vora; Lenna A Martyak; Huiying Yang; Bei Hu; Ying-Chao Lin; Gregory Keenan; Joanne Price; Carol J Landers; John S Adams; Stephan R Targan Journal: J Clin Gastroenterol Date: 2006-01 Impact factor: 3.062
Authors: Francisco A Sylvester; Nancy Wyzga; Jeffrey S Hyams; Patricia M Davis; Trudy Lerer; Katherine Vance; Gillian Hawker; Anne M Griffiths Journal: Inflamm Bowel Dis Date: 2007-01 Impact factor: 5.325
Authors: Jeffrey Hyams; James Markowitz; Anthony Otley; Joel Rosh; David Mack; Athos Bousvaros; Subra Kugathasan; M Pfefferkorn; Vasundhara Tolia; Jonathan Evans; William Treem; Robert Wyllie; Robert Rothbaum; J del Rosario; Aubrey Katz; Adam Mezoff; M Oliva-Hemker; Trudy Lerer; Anne Griffiths Journal: J Pediatr Gastroenterol Nutr Date: 2005-10 Impact factor: 2.839
Authors: Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack Journal: Gastroenterology Date: 2006-11-29 Impact factor: 22.682
Authors: J Hinojosa; F Gomollón; S García; G Bastida; J L Cabriada; C Saro; D Ceballos; M Peñate; M A Gassull Journal: Aliment Pharmacol Ther Date: 2007-02-15 Impact factor: 8.171